Inhaled corticosteroids raise pneumonia risk

September 18, 2013

A University of Alberta researcher says health professionals should be cautious about prescribing inhaled corticosteroids to high-risk patients such as pneumonia survivors, citing a twofold risk for repeat infection.

Dean Eurich led a research team that examined inhaled corticosteroid use among elderly patients for a clinical study. The team evaluated more than 6,200 seniors who survived an initial episode of pneumonia but were still at of developing another bout of infection.

Over the five-year study, 653 seniors had a repeat episode—and inhaled corticosteroid use was associated with a 90 per cent increase in risk for these repeat occurrences compared with the rate among those not using the drugs.

"Given the evidence starting to emerge on , health professionals have to use their own to try and determine which patients should remain on the drugs, especially for patients with pneumonia," said Eurich, an associate professor in the School of Public Health and trained pharmacist.

Inhaled corticosteroids are used to treat asthma and and emphysema—as well as other such as a nagging cough. Several smaller studies have examined the risk of developing pneumonia, but the U of A team is the first to look at such a large group of high-risk seniors.

More research is needed as to why these drugs pose a greater pneumonia risk, but for patients taking them, Eurich has healthy advice: listen to your health professional, wash your hands often and get vaccinated to reduce your risk of respiratory infections.

"Continue on your medications as your health professional has told you to use them. If you're feeling unwell, if you are coughing or wheezing more, are more short of breath than usual, have chest pain when breathing deeply or coughing, feel fatigued, or develop a fever, see a physician sooner rather than later."

Research begins at bedside

Eurich says the new findings would not have been possible without talented collaborators such as Alberta Diabetes Institute colleague Sumit Majumdar of the Faculty of Medicine & Dentistry and the faculty's former dean, Tom Marrie, now at Dalhousie University, as well as data and support from Alberta Health and Alberta Health Services.

"When we set up this cohort, there was a ton of support from the University of Alberta and because there's such a good relationship between the university and the health system, it easily facilitated our work," he said. "When researchers have access to data for population-based studies, we can look at safety issues with medications in real-world patients."

The research was published last month in the peer-reviewed journal Clinical Infectious Diseases.

Explore further: Long-term ICS use reduces pleural effusion in patients with community acquired pneumonia

Related Stories

Recommended for you

Raising the curtain on cerebral malaria's deadly agents

December 6, 2016

Using state-of-the-art brain imaging technology, scientists at the National Institutes of Health filmed what happens in the brains of mice that developed cerebral malaria (CM). The results, published in PLOS Pathogens, reveal ...

Re-emergence of syphilis traced to pandemic strain cluster

December 5, 2016

Over the last few decades, an age-old infectious disease has been re-emerging globally: syphilis. Using techniques to analyze low levels of DNA, an international research team headed by the University of Zurich has now shown ...

New mechanism to control human viral infections discovered

December 5, 2016

A team of researchers, co-led by a University of California, Riverside professor, has found a long-sought-after mechanism in human cells that creates immunity to influenza A virus, which causes annual seasonal epidemics and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.